GlassScriptPhysician profile
Jean Serna
NPI 1831876697
$1,740.46
in general payments reported to CMS, 2019-2025
26 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $541 · 2024: $907 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $223.31 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $215.04 | 2023-2025 | |
| Abbvie INC. | $188.34 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.31 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $113.23 | 2023-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $71.59 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $62.18 | 2023-2024 | Rexulti |
| Cequr Corporation | $61.72 | 2024-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $60.88 | 2024 | |
| Insulet Corporation | $57.30 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $51.97 | 2023-2024 | Verquvo |
| Lilly USA, LLC | $51.14 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $49.90 | 2023-2024 | |
| Radius Health, INC. | $44.80 | 2024 | |
| Boston Scientific Corporation | $43.84 | 2023-2024 | Watchman Flx, Watchman Access System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.23 | 2024 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $38.27 | 2023 | Jornay Pm |
| Shield Therapeutics INC | $37.68 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.48 | 2024-2025 | Caplyta |
| Evoke Pharma, INC. | $32.99 | 2024 | |
| Alexion Pharmaceuticals, INC. | $32.74 | 2023 | Strensiq |
| Abiomed | $28.72 | 2024 | Impella |
| Daiichi Sankyo INC. | $19.99 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $18.12 | 2025 | Invega Sustenna |
| Exact Sciences Corporation | $12.85 | 2023 | Cologuard Collection Kit |
| Athena Bioscience, LLC | $12.84 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Serna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.